Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: Effect on formulation and characterization parameters

European Journal of Pharmaceutical Sciences

Volumn 78, Issue , 2015, Pages 54-66

  Shah, Brijesh ^a   Khunt, Dignesh ^a   Bhatt, Himanshu ^a   Misra, Manju ^a   Padh, Harish ^b  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

^b SARDAR PATEL UNIVERSITY   (India)

Author keywords

Brain targeting; Compritol 888 ATO; Factorial design; Intranasal route; Rivastigmine; Solid lipid nanoparticles

Indexed keywords

GLYCEROL BEHENATE; POLOXAMER; POLYSORBATE 80; RIVASTIGMINE; SOLID LIPID NANOPARTICLE; STEARIC ACID; CHOLINESTERASE INHIBITOR; LIPID; NANOPARTICLE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG QUALITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; EX VIVO STUDY; FACTORIAL DESIGN; HISTOPATHOLOGY; HYDROPHILICITY; IN VITRO STUDY; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITY BY DESIGN; ULTRASOUND; X RAY DIFFRACTION; ZETA POTENTIAL; ANATOMY AND HISTOLOGY; ANIMAL; CHEMISTRY; DRUG EFFECTS; GOAT; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; SOLUBILITY;

ADMINISTRATION, INTRANASAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; GOATS; LIPIDS; NANOPARTICLES; NASAL MUCOSA; RIVASTIGMINE; SOLUBILITY;

EID: 84936995824     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.07.002     Document Type: Article

References (56)

1. G. Abdelbary, and R.H. Fahmy Diazepam-loaded solid lipid nanoparticles: design and characterization Aaps PharmSciTech 10 2009 211 219
2. M.I. Alam, S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, and M. Akbar Strategy for effective brain drug delivery Eur. J. Pharm. Sci. 40 2010 385 403
3. M. Aoki, T.A. Ring, and J.S. Haggerty Analysis and modeling of the ultrasonic dispersion technique Adv. Ceram. Mater. 2 1987 209 212
4. P. Arora, S. Sharma, and S. Garg Permeability issues in nasal drug delivery Drug Discov. Today 7 2002 967 975
5. K. Arumugam, G. Subramanian, S. Mallayasamy, R. Averineni, M. Reddy, and N. Udupa A study of rivastigmine liposomes for delivery into the brain through intranasal route Acta Pharm. 58 2008 287 297
6. R.P. Bagwe, J.R. Kanicky, B.J. Palla, P.K. Patanjali, and D.O. Shah Improved drug delivery using microemulsions: rationale, recent progress, and new horizons Crit. Rev. Ther. Drug. Carr. Syst. 18 2001 77 140
7. H. Bhatt, B. Naik, and A. Dharamsi Solubility enhancement of budesonide and statistical optimization of coating variables for targeted drug delivery J. Pharm. 2014 10.1155/2014/262194
8. A.M. Brioschi, S. Calderoni, G.P. Zara, L. Priano, M.R. Gasco, and A. Mauro Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenges H.S. Sharma (Ed.), Progress in Brain Research 180 2009 Elsevier London (Chapter 11)
9. J. Chang, Y. Jallouli, A. Barras, N. Dupont, and D. Betbeder Drug delivery to brain using colloidal carriers H.S. Sharma, Progress in Brain Research 180 2009 Elsevier London (Chapter 1)
10. P. Costa, and J.M.S. Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
11. L. Costantino, G. Tosi, B. Ruozi, L. Bondioli, M.A. Vandeli, and F. Forni Colloidal systems for CNS drug delivery H.S. Sharma, Progress in Brain Research 180 2009 Elsevier London (Chapter 3)
12. S. Das, W.K. Ng, P. Kanaujia, S. Kim, and R.B. Tan Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables Colloids Surf., B 88 2011 483 489
13. S. Dash, P.N. Murthy, L. Nath, and P. Chowdhury Kinetic modeling on drug release from controlled drug delivery systems Acta Pol. Pharm. 67 2010 217 223
14. S. Eyal, P. Hsiao, and J.D. Unadkat Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol. Ther. 123 2009 80 104
15. M. Fazil, S. Md, S. Haque, M. Kumar, S. Baboota, J. Kaur Sahni, and J. Ali Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting Eur. J. Pharm. Sci. 47 2012 6 15
16. K. Florence, L. Manisha, B.A. Kumar, K. Ankur, M.A. Kumar, and M. Ambikanandan Intranasal clobazam delivery in the treatment of status epilepticus J. Pharm. Sci. 100 2011 692 703
17. G.T. Grossberg Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on Curr. Ther. Res. 64 2003 216 235
18. K. Hippalgaonkar, G.R. Adelli, K. Hippalgaonkar, M.A. Repka, and S. Majumdar Indomethacin-loaded solid lipid nanoparticles for ocular delivery: development, characterization, and in vitro evaluation J. Ocul. Pharmacol. Ther. 29 2013 216 228
19. ICH Q9, 2006. US Food and Drug Administration. Guidance for industry: Q9 quality risk management, June. Available from: < http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Quality/Q8-R1/Step4/Q8-R2-Guideline.pdf >.
20. ICH Q8 (R2), 2009. Pharmaceutical development, August. Available from: < http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073511.pdf >.
21. L. Illum Transport of drugs from the nasal cavity to the central nervous system Eur. J. Pharm. Sci. 11 2000 1 18
22. K.R. Jadhav, S.L. Shetye, and V.J. Kadam Design and evaluation of microemulsion based drug delivery system Int. J. Adv. Pharm. Sci. 1 2010 156 166
23. Kaur, I.P., Bhandari, R., 2013. Solid lipid nanoparticles entrapping hydrophilic/amphiphilic drug and a process for preparing the same. WO 2013/105101 A1.
24. J. Kreuter Nanoparticulate systems for brain delivery of drugs Adv. Drug Deliv. Rev. 47 2001 65 81
25. M. Kumar, K. Pathak, and A. Misra Formulation and characterization of nanoemulsion-based drug delivery system of risperidone Drug Dev. Ind. Pharm. 35 2009 387 395
26. Kumar, A., Pandey, A.N., Jain, S.K., 2014a. Nasal-nanotechnology: revolution for efficient therapeutics delivery. Drug Deliv. < http://informahealthcare.com/doi/pdf/10.3109/10717544.2014.920431 >.
27. M. Kumar, V. Kakkar, A.K. Mishra, K. Chuttani, and I.P. Kaur Intranasal delivery of streptomycin sulfate (STRS) loaded solid lipid nanoparticles to brain and blood Int. J. Pharm. 461 2014 223 233
28. R.B. Lazenby Handbook of Pathophysiology fourth ed. 2010 Lippincott Williams & Wilkins Philadelphia
29. J. Liu, T. Gong, C. Wang, Z. Zhong, and Z. Zhang Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization Int. J. Pharm. 340 2007 153 162
30. W. Mehnert, and K. Ma¨der Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2012 165 196
31. Mittal, D., MD, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., Ali J., 2014. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. < http://informahealthcare.com/doi/pdf/ 10.3109/10717544.2014.907372 >.
32. R.H. Muller, K. MaÈder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177
33. W.M. Pardridge Drug transport across the blood-brain barrier J. Cereb. Blood Flow Metab. 32 2012 1959 1972
34. S. Patel, S. Chavhan, H. Soni, A.K. Babbar, R. Mathur, A.K. Mishra, and K.K. Sawant Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route J. Drug Target. 19 2011 468 474
35. Z. Rahman, A.S. Zidan, and M.A. Khan Non-destructive methods of characterization of risperidone solid lipid nanoparticles Eur. J. Pharm. Biopharm. 76 2010 127 137
36. L.H. Reddy, and R.S.R. Murthy Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation AAPs PharmSciTech 6 2005 E158 E166
37. B. Rohit, and K.I. Pal A method to prepare solid lipid nanoparticles with improved entrapment efficiency of hydrophilic drugs Curr. Nanosci. 9 2013 211 220
38. R.C. Rowe, P.J. Sheskey, and M.E. Quinn Handbook of Pharmaceutical Excipients sixth ed. 2009 Pharmaceutical Press and American Pharmacist Association
39. E. Scarpini, P. Schelterns, and H. Feldman Treatment of Alzheimer's disease; current status and new perspectives Lancet Neurol. 2 2003 539 547
40. U. Seju, A. Kumar, and K.K. Sawant Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies Acta Biomater. 7 2011 4169 4176
41. L.C. Serpell Alzheimer's amyloid fibrils: structure and assembly Biochim. Biophys. Acta 1502 2000 16 30
42. M. Shah, and K. Pathak Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full-factorial design AAPS PharmSciTech 11 2010 489 496
43. Shah, B.M., Misra, M., Shishoo, C.J., Padh, H., 2014. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. < http://informahealthcare.com/doi/pdf/10.3109/10717544.2013.878857 >.
44. S. Singh, A.K. Dobhal, A. Jain, J.K. Pandit, and S. Chakraborty Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovudine Chem. Pharm. Bull. 58 2010 650 655
45. R.K. Subedi, K.W. Kang, and H.K. Choi Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin Eur. J. Pharm. Sci. 37 2009 508 513
46. J.S. Taurozzi, V.A. Hackley, and M.R. Wiesner Ultrasonic dispersion of nanoparticles for environmental, health and safety assessment-issues and recommendations Nanotoxicology 5 2011 711 729
47. H.P. Thakkar, J.L. Desai, and M.P. Parmar Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil Asian J. Pharm. 8 2014 81 89
48. V. Venkateswarlu, and K. Manjunath Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles J. Control. Rel. 95 2004 627 638
49. K. Vivek, H. Reddy, and R.S. Murthy Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles AAPS PharmSciTech 8 2007 16 24
50. C. Vora, R. Patadia, K. Mittal, and R. Mashru Risk based approach for design and optimization of stomach specific delivery of rifampicin Int. J. Pharm. 455 2013 169 181
51. Wechsler, J., 2008. FDA proposes flexible oversight for quality systems. Pharm. Technol. Available from: < http://www.pharmtech.com/node/227632?rel=canonical >.
52. K. Westesen, H. Bunjes, and M.H.J. Koch Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential J. Control. Release 48 1997 223 236
53. B.R. Williams, A. Nazarians, and M.A. Gill A review of rivastigmine: a reversible cholinesterase inhibitor Clin. Ther. 25 2003 1634 1653
54. B. Wilson, M.K. Samanta, K. Santhi, K.P.S. Kumar, N. Paramakrishnan, and B. Suresh Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease Brain Res. 1200 2008 159 168
55. Z.Z. Yang, Y.Q. Zhang, Z.Z. Wang, K. Wu, J.N. Lou, and X.R. Qi Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration Int. J. Pharm. 452 2013 344 354
56. D. Yates, and D.M. McLoughlin The molecular pathology of Alzheimer's disease Psychiatry 7 2008 1 5